The Benefits of Jakafi for Patients With PV

Patients with PV tend to be very symptomatic, but Jakafi can help.

Jeanne M. Palmer, M.D., hematologist oncologist at the Mayo Clinic in Arizona discusses the benefit of Jakafi (ruxolitinib) for patients with polycythemia vera (PV) — a type of myeloproliferative neoplasm.

Patients with PV tend to be very symptomatic, and Jakafi provides good symptom control compared to some other PV treatments that have their own set of risks and side effects.

Related Content:

CURE TVMPN
LeVar Burton Gives ‘Voice and Visibility’ to Patients with MPNs Through Storytelling and Advocacy
LeVar Burton Helping the MPN Community Through Advocacy and Storytelling
MPN Heroes® Recognition Program 2021